These results demonstrate that BID may affect the tumor immune microenvironment through multiple pathways, which provides a new perspective for exploring whether BID can be used as a novel therapeutic target and a predictor of immunotherapy response in ccRCC. The gene discussed is BID; the disease is nonpapillary renal cell carcinoma.